This was different in those with CKD (groups eGFR ≥60/Alb+, eGFR <60/Alb−, and eGFR <60/Alb+): RAASi (77%), β-blockers (62%), and Calcium antagonists (31%). Here, ALB is linked to chronic kidney disease.